Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

8.7%

2 terminated/withdrawn out of 23 trials

Success Rate

91.3%

+4.8% vs industry average

Late-Stage Pipeline

13%

3 trials in Phase 3/4

Results Transparency

48%

10 of 21 completed trials have results

Key Signals

10 with results

Enrollment Performance

Analytics

N/A

8(57.1%)

Phase 4

3(21.4%)

Phase 2

3(21.4%)

14Total

N/A(8)

Phase 4(3)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials

NCT01073566Phase 2Completed

Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections

Role: collaborator

NCT04028960Phase 2Terminated

IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

Role: collaborator

NCT03040414Not ApplicableCompleted

Fuzzy Logic Automated Insulin Regulation

Role: collaborator

NCT01170208Not ApplicableCompleted

Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes

Role: collaborator

NCT01237301Not ApplicableCompleted

Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes

Role: collaborator

NCT01184014Phase 4Completed

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

Role: collaborator

NCT02523131Not ApplicableCompleted

Home Testing of Day and Night Closed Loop With Pump Suspend Feature

Role: collaborator

NCT01089569Not ApplicableCompleted

Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

Role: collaborator

NCT01535612Not ApplicableCompleted

Study of PaQ™ (a Simple Patch on Insulin Delivery Device) in Patients With Type 2 Diabetes Mellitus

Role: collaborator

NCT00948311Completed

Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.

Role: collaborator

NCT00202033Phase 4Completed

Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes

Role: collaborator

NCT00945711Completed

Characteristics of Persons With an Eating Disorder and Type 1 Diabetes

Role: collaborator

NCT01237314Completed

The Impact of Food on Blood Sugar in People With Type 2 Diabetes

Role: collaborator

NCT00818142Completed

Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder

Role: collaborator

NCT00818077Completed

Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food

Role: collaborator

NCT00824603Completed

Impact of Continuing Medical Education (CME) Insulin Program

Role: collaborator

NCT00993824Phase 2Completed

Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes

Role: collaborator

NCT00813280Completed

Barriers to the Implementation of Complete Insulin Order Sets

Role: collaborator

NCT00805506Completed

Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With Diabetes

Role: collaborator

NCT01072565Not ApplicableCompleted

Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring

Role: collaborator